In Q1 2026, UK private companies in the sub-£50M segment raised £1.66bn across 1,403 fundraises — the lowest opening quarter since 2020. SyndicateRoom's analysis of 28 quarters of Companies House share-allotment filings shows deal volume in the lower band of its seven-year range, capital continuing the slide that began in 2024, and the market concentrating at the top end.
UK private equity headlines in Q1 2026 will be dominated by three names: NScale, Wayve and ElevenLabs. Between them, those three rounds account for the better part of £2bn — a meaningful share of all UK private capital reported for the quarter. Each is a US-style growth round, raised largely from global capital pools, with a UK subsidiary receiving a share of the proceeds.
We strip rounds like these out of our headline figures. This article is about what is underneath, and why it matters as much as the top.
SyndicateRoom parses every SH01 — the statutory return of allotment of shares — lodged with Companies House by UK private companies, going back to 2016. Each filing is the legal record of new shares issued, and is filed within one month of the allotment date. We structure them, strip out filings that are not genuine private fundraising (intra-group capitalisations, PLC placings, foreign-currency parent-to-subsidiary transfers), and aggregate into quarterly views. Across SH01s and CS01s we have processed roughly 1.5 million filings for over 250,000 UK companies.
The dataset behind this article covers 28 quarters and roughly 50,000 distinct company-quarter funding events. Every figure here can be traced back to a specific filing.
It is, deliberately, a narrower lens than press-release-based analysis. We do not count announced rounds that have not filed. We do not count advance subscription agreements or convertibles that have not yet converted into issued shares. And we do not count rounds raised by foreign parent companies and only partially flowed to UK subsidiaries, even when those rounds are reported as "UK deals" elsewhere. What our lens preserves is the part of the market that maps to where UK angels, EIS funds and SEIS funds actually deploy: the 1,400–2,200 companies per quarter raising sub-£50m from UK investors.
The UK private market is power-law distributed. In any given quarter, somewhere between 10 and 30 companies raise £50m or more, and those rounds can swing headline totals by billions. They are also increasingly the product of capital decisions made well outside the UK.
When ElevenLabs raises at the US parent level, the round shows up in our system as the Inc. company with funds passing through to the UK entity, often months after the announcement. Other late-stage entities use structures complex enough that the actual UK-domiciled movement is difficult to discern from filings alone, and you end up relying on announced figures. These are real businesses with real UK operations, and the power-law nature of the market means they matter as indicators of whether the UK ecosystem is producing unicorns at all.
They are not, however, part of the same market that EIS investors, angels and IFAs are deploying into. The capital that built those rounds is largely not UK angel money. Counting it into a headline labelled "UK venture" describes something real, but not the part of the market most UK private investors can access. So we report the top end separately, and lead on the segment that more closely reflects the market our audience operates in.
In Q1 2026, 1,403 UK private companies raised under £50m each. Combined, they brought in £1.66bn. Three things stand out.
First, deal volume sits in the lower band of the seven-year range. Q1 has historically been the strongest filing quarter of the year — 2024 Q1 saw 1,979 companies, 2023 Q1 saw 2,047, 2021 Q1 saw 2,050. Q1 2026 sits materially below all of those. Filing lag will pull this number up over the next 4–6 weeks as late SH01s arrive (the statutory window is one month from the allotment date, but in practice the tail runs longer), but the gap to trend is wide enough that even a generous late cohort leaves Q1 2026 as one of the quieter starts in the series.
Second, total capital into the sub-£50M segment has continued the slide it began in 2024. The segment peaked above £3.6bn in 2022 Q1 and has stepped down each year since: £2.59bn in 2023 Q1, £2.52bn in 2024 Q1, £1.81bn in 2025 Q1, and £1.66bn in Q1 2026. That is a sustained, multi-year softening.
Third, the chart below is the most useful single view of the dataset. Bars show sub-£50M £ raised each quarter; the line shows the number of companies raising. Volume has narrowed steadily since the 2022 peak, which itself reflected post-COVID exuberance more than any new steady state. Some of what we are seeing now is the predictable reversion to mean. Some is plausibly the effect of harder economic conditions for early-stage businesses raising capital — higher rates, longer fundraising cycles, more cautious investors. Most likely it is both.
Sub-£50M UK private equity issuance by quarter, 2019 Q1 – 2026 Q1. Bars: £M raised. Line: number of companies. Q1 2026 in-flight; figures will rise as late filings arrive. Source: SyndicateRoom analysis of Companies House SH01 filings.
Stepping back from the quarterly noise, the annual picture sharpens the trend. Sub-£50M capital peaked at £11.9bn in 2022 (the post-pandemic high) and has stepped down each year since: £9.6bn in 2023, £9.5bn in 2024, £7.9bn in 2025. Deal count has narrowed in parallel, from 7,551 companies in 2022 to 5,915 in 2025.
Q1 has historically accounted for an average of around 27% of full-year sub-£50M capital (26.8% across 2022-2025, more stable than I would have expected before checking). Applying that share to Q1 2026's £1.66bn gives a rough full-year 2026 implied total of £6.2bn, on a deal count near 5,000 companies. That would be the lowest annual reading in the dataset and a continuation of the four-year slide.
This is a straight extrapolation, not a model — H2 weighting could push the number higher, particularly if the Budget passes without unfriendly EIS or capital-gains changes, and we will refresh the forecast each quarter as actuals land. But on balance I do not expect a return to 2022's £11.9bn over the next twelve months, or even to 2024's £9.5bn. The deal-count line in particular has been narrowing for four consecutive years now, and that is harder to reverse than a one-quarter capital figure.
Sub-£50M UK private equity issuance by year, 2019 – 2026. 2026 is forecast using Q1 2026 actual data extrapolated by the historical Q1 share of full year (26.8%, 2022–2025 average). Source: SyndicateRoom analysis of Companies House SH01 filings.
Strip out the mega-deals, and the AI-dominated narrative that drives headline UK venture coverage becomes more muddled. In the sub-£50M segment in Q1 2026, AI received £100m across 55 companies — a meaningful slice, but neither the largest sector by capital nor close to the dominant share its mega-deal cousins suggest.
The sectors carrying UK ecosystem capital in Q1 2026 are more conventional than press coverage implies:
Fintech: £234m across 116 companies. The largest single sector by capital deployed in the sub-£50M segment. Broad-based, not concentrated.
SaaS: £212m across 173 companies. The single largest sector by deal count — the workhorse of UK private investment.
Life sciences (biotech, medtech, healthtech combined): £242m across 168 companies. Diffuse, no mega-deals propping it up, and quietly larger than fintech once aggregated. Often underappreciated in UK venture commentary.
Deeptech: £93m across 48 companies. Smaller but punchy average deal size.
AI (sub-£50M only): £100m across 55 companies. A real share of activity, but a fraction of its mega-line dominance.
The pattern matters, with one important refinement. Every one of these leading sectors — fintech, SaaS, life sciences, deeptech — will be using AI in some form, sometimes as the core of the product. So the AI impact is showing up across the data; it is just doing so embedded inside a fintech, SaaS or life-sciences classification rather than as a pure-play AI tag. The pure-play AI line is small in the sub-£50M segment; AI as an enabling technology is everywhere. For advisers thinking about EIS and SEIS portfolio construction, the relevant exposure is to the sectors carrying broad capital, not to "AI" as a category.
For an adviser sitting in front of a client with an EIS or SEIS allocation question this tax year, two things follow from the data.
First, the recovery narrative implied by headline UK venture figures is not really describing the part of the market UK private investors are exposed to. Headline capital is concentrating into a small number of foreign-led mega-rounds, while the broader ecosystem is raising less, from fewer cheques, than at almost any point in the post-pandemic window. Put simply, if a client is reading the press and thinks UK venture is back to 2021 levels, the part of the market their EIS portfolio touches is not.
Second, the sectors leading the sub-£50M market in Q1 2026 are not the ones leading the headlines. Fintech, SaaS and life sciences are carrying the broader ecosystem; pure-play AI is a smaller slice. What this analysis suggests is that an EIS-accessible portfolio constructed broadly across the most-active sectors will end up substantially exposed to AI as an enabling technology anyway, without needing to overweight pure-play AI names to get there.
Neither observation is a call to act this week. Both are reasons to look closely at how the rest of 2026 unfolds.
Every figure here is derived from statutory SH01 filings retrieved from Companies House and structured by our internal system. Across SH01s and CS01s we have processed roughly 1.5 million filings covering over 250,000 UK companies. We strip out PLCs, par-value intra-group capitalisations, allotments in foreign currencies, and rounds where a corporate parent has taken majority control of a UK subsidiary. The "sub-£50M" cut separates the broad UK ecosystem from the mega-deal layer.
It is worth noting two limitations openly. First, a small share of mega-deals remain unclassified by sector — typically newly-incorporated holding companies and SPVs that do not yet have the trading history to be sector-tagged. We are tightening the mega-deal definition further in the next iteration of the dataset to exclude single-deal SPVs and very young entities raising at unusual scale, which will modestly reduce the mega total in future quarters. Second, filings for the most recent quarter are still arriving — Q1 2026 numbers will rise over the coming weeks as late SH01s land, and the directional reads above are robust to that, but the absolute totals are not yet final.
Full methodology, filter logic and known limitations are documented below, at the bottom of this article.
This is the first piece in what I intend as a quarterly series tracking the sub-£50M UK private market through statutory filings. Over the next few quarters we plan to publish:
Sector concentration in the sub-£50M segment over time — whether the fintech / SaaS / life-sciences split holds across cycles, or whether Q1 2026 is unusual.
Regional mix — where capital is actually being deployed outside London.
Funding-stage transitions — what does the 2021 cohort look like 4–5 years on, and how does that compare to the 2018 cohort at the equivalent point?
There is also a piece I would like to write on how filings-based data compares against announced-deal data over a full cycle, to put a number on the divergence we are flagging in this piece. That requires another quarter of clean data and is on the list for later in the year.
If you are a wealth manager, IFA or institutional allocator who would find a regular feed of this data useful before publication, the team is happy to share quarterly briefings — just drop us an email.
Figures are derived from statutory SH01 (Return of Allotment of Shares) filings lodged with Companies House, which UK private companies must file within one month of issuing new shares. We parse each filing's share count, per-share price, share class, and allotment date, and aggregate by company within each calendar quarter. A company that files multiple SH01s in a quarter counts once, with money raised calculated as shares × price-per-share.
To isolate genuine private funding rounds from corporate housekeeping, we apply four filters: we exclude PLCs (whose allotments are public-market placings); we cap obvious filer errors (per-share price ≤ £10,000 and total allotment ≤ £500M, since some filers wrongly enter aggregate values in the per-share field); we drop allotments at round par/nominal prices (£0.01, £1, £100, etc.) that signal intra-group capitalisations rather than priced rounds; and we exclude companies whose most recent confirmation statement shows a single corporate shareholder holding more than 50%, which almost always indicates an intra-group capital movement rather than market funding.
Only GBP-denominated allotments are included. We additionally separate "mega-deals" (£50M+ in a quarter) from the sub-£50M base, because a handful of outsized rounds each quarter otherwise swing the headline totals and obscure the broader ecosystem.
The picture is necessarily incomplete and skews toward an undercount, especially for recent quarters. SH01s have a one-month filing window plus our own processing lag, so the most recent six weeks fill in over time; quarter-on-quarter comparisons are more reliable than the latest absolute total. GBP-only filtering systematically misses UK subsidiaries of overseas-parented companies, whose headline capital is often raised at the foreign parent and never appears in UK filings or appears only as later, smaller intra-group injections.
Our company coverage is not yet exhaustive, so absolute figures are a lower bound. And because the source is statutory equity allotments, the data excludes announced-but-unfiled rounds, advance subscription agreements, and convertibles, meaning headline totals may read structurally lower than announced deal trackers even though company/deal counts land within a few percent.
Please note: our office hours are weekdays, 9.30am - 5.30pm.
